In contrast, over a median follow-up of 7 months Patorno et al.102 reported a lower relative risk of myocardial infarction with SGLT2i compared to GLP1-RA in US claims data specific to individuals with a history of CVD (n=156,825; HR 0.82 [95%CI 0.71, 0.95]), with no differences in stroke outcomes irrespective of CVD status. The gene discussed is GLP1R; the disease is myocardial infarction.